3 Pharma Stocks Flashing 'Buy' Signals in December

[Investing Insights Daily]( December 8th, 2023 SPONSOR [Rare Chance to Be an Early Investor in AI Energy Breakthrough]( Technology expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors. [Just go here for full details.]( [3 Pharma Stocks Flashing 'Buy' Signals in December]( The pharmaceutical industry is growing at a rapid pace with a significant surge in healthcare expenditure worldwide due to the rising geriatric population and increasing prevalence of chronic illnesses. Also, consistent research and development (R&D) efforts and rapid technological advancements boost the industry’s prospects. Given the industry’s promising outlook, it could be wise to buy quality pharma stocks Collegium Pharmaceutical, Inc. ([COLL]( – [Get Rating]( Eton Pharmaceuticals, Inc. ([ETON]( – [Get Rating]( and GSK plc ([GSK]( – [Get Rating]( in December for solid gains. As per Statista, revenue in the pharmaceutical market is projected to reach $1.12 trillion in 2023. Further, the market is expected to grow at a [CAGR of 5.8%]( during the forecast period (2023-2028), resulting in a market volume of $1.48 trillion by 2028. In a global comparison, the United States will generate the majority of revenue (approximately $603.40 billion this year). In recent years, the pharma industry has undergone a swift transformation with a greater focus on research and development. On average, pharma companies spend [more than 21% of their revenues on R&D]( for the formation and discovery of new drugs and solutions. Last year, the R&D expenditure of PhRMA members within the U.S. pharmaceutical industry [totaled $101 billion](. The global pharmaceutical manufacturing market is estimated to reach $929.90 billion, [expanding at a CAGR of 7.6% from 2023 to 2030](. The market experienced significant growth due to numerous technological advancements, cost-effective manufacturing methods, and increased R&D spending. Advanced technologies like AI, genetic editing, big data analysis, and additive manufacturing are rapidly being adopted to improve efficiency and productivity in pharmaceutical manufacturing processes. The global AI in pharmaceutical market is expected to [reach $11.81 billion by 2032]( growing at a CAGR of 29.30% during the forecast period (2023–2032). With these encouraging trends in mind, let’s look at the fundamentals of the three best [Medical – Pharmaceuticals]( stocks, beginning with… Continue reading at [STOCKNEWS.com]( NOTE: If URLs do not appear as live links in your e-mail program, please cut and paste the full URL into the location or address field of your browser. [Privacy Policy]( | [Terms & Conditions]( This email contains a paid advertisement.This is not a solicitation for the purchase or sale of securities. Readers are encouraged to conduct their own research and due diligence, and/or obtain professional advice, prior to making any investment decision. Advertisements and sponsorships are provided as a service to Stock News users. Stock News is not responsible for their content, services or products. The statements and opinions contained in this advertisement are not those of Stock News, and Stock News disclaims any liability for or arising from such statements and opinions. You are hereby advised that Stock News is receiving a fee as compensation for the distribution of this advertisement. [Click here to unsubscribe]( Copyright © 2023 Investing Insights Daily News, part of StockNews.com - POWR Stock Rating, Market Outlook & Investment Insights Magnifi Communities, 1 Penn Plaza, Suite 3910, New York, NY 10019